A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Have serious preexisting medical conditions.
• •Have received treatment with a drug predominantly targeting Ang2 activity.
• •Have symptomatic central nervous system (CNS) malignancy or metastasis.
• •Have current hematologic malignancies.
• •Have an active fungal, bacterial, and/or known viral infection.
• •Have a corrected QT interval using Fridericia's correction (QTcF) of \>470 msec on screening electrocardiogram (ECG) at several consecutive days of assessment.
• •Have a known sensitivity to mAbs or other therapeutic proteins.
• •Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.
• •Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 3 months prior to receiving treatment.
• •Receive anticoagulation therapy at therapeutic dose.
• •Have experienced any arterial or venothrombotic or thromboembolic events within 6 months prior to study treatment.
• •Have liver cirrhosis with a Child-Pugh class B or worse or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.
• •The participant is pregnant prior to randomization or breastfeeding.
• •The participant has sensory peripheral neuropathy ≥ Grade 2 (Part E only).